.. Les-effets-secondaires, 35 1.5.1. Les effets secondaires 35 1.5.1.1. Les troubles gastro-intestinaux, p.36

L. Echecs-de, Les rétentions trophoblastiques et grossesses arrêtées non évacuées, p.37

L. Douleur-dure-en-moyenne, 62 jours avec un écart-type=4,15. Figure 31: Durée des douleurs Les saignements : Ils durent en moyenne 10,45 jours avec un écart-type = 4,48, Le minimum est de 2 jours et le maximum relevé de 21 jours

L. Nausées and . Vomissements, Ils sont présents chez 41

I. Sääv, C. Fiala, J. Hämäläinen, O. Heikinheimo, and K. Gemzell-danielsson, Medical abortion in lactating women ??? low levels of mifepristone in breast milk, Acta Obstetricia et Gynecologica Scandinavica, vol.89, issue.5, pp.618-640, 2010.
DOI : 10.3109/00016341003721037

R. Mifépristone, E. Aubeny, and V. Targosz, Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol, N Engl J Med Mai, vol.27328, pp.1509-1513, 1993.

B. Winikoff, I. Sivin, and K. Coyaji, "Safety, Efficacy, and Acceptability of Medical Abortion in China, Cuba, and India: A Comparative Trial of Mifepristone-Misoprostol versus Surgical Abortion.", Studies in Family Planning, vol.28, issue.2, pp.431-438, 1997.
DOI : 10.2307/2138124

I. Spitz, C. Bardin, L. Benton, and A. Robbins, Early pregnancy termination with mifepristone and misoprostol in the United States, N Engl J Med Avril, vol.30338, pp.1241-1248, 1998.

E. Aubény and G. Chatellier, A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion, The European Journal of Contraception & Reproductive Health Care, vol.312, issue.3, pp.171-177, 2000.
DOI : 10.1016/S0029-7844(98)00436-0

R. Kulier, A. Gülmezoglu, G. Hofmeyr, L. Cheng, and A. Campana, Medical methods for first trimester abortion, Cochrane Database Syst Rev Online, issue.2, p.2855, 2004.

M. Lievre and R. Sitruk-ware, Meta-analysis of 200 or 600 mg mifepristone in association with two prostaglandins for termination of early pregnancy, Contraception, vol.80, issue.1, pp.95-100, 2009.
DOI : 10.1016/j.contraception.2009.01.011

J. Bartley, S. Tong, D. Everington, and D. Baird, Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation, Human Reproduction, vol.16, issue.10, pp.2098-102, 2001.
DOI : 10.1093/humrep/16.10.2098

P. Svendsen, C. Rørbye, T. Vejborg, and L. Nilas, Comparaison of gemeprost and vaginal misoprostol in first trimester mifepristone-induced abortion. Contraception, pp.28-32, 2005.

J. Aubert, T. Bejan-angoulvant, and A. Jonville-bera, Pharmacologie du misoprostol (donn??es pharmacocin??tiques, tol??rance et effets t??ratog??nes), Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.43, issue.2, pp.114-136, 2014.
DOI : 10.1016/j.jgyn.2013.11.006

A. Aronsson, C. Fiala, and O. Stephansson, Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol, Hum Reprod, pp.1912-1920, 2007.

O. Tang, H. Schweer, H. Seyberth, S. Lee, and P. Ho, Pharmacokinetics of different routes of administration of Misoprostol. Hum Reprod Research Group on Postovulatory Methods of Fertility Regulation. Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled non inferiority trial, FebBJOG, vol.17117, issue.210, pp.332-336, 2002.

E. Raymond, C. Shannon, M. Weaver, and B. Winikoff, First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review, Contraception, vol.87, issue.1, pp.26-37, 2013.
DOI : 10.1016/j.contraception.2012.06.011

J. Chai, C. Wong, and P. Ho, A randomized clinical trial comparing the short-term sideeffects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation. Contraception, pp.480-485, 2013.

E. Schaff, S. Fielding, and C. Westhoff, Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy, Contraception, vol.66, issue.4, pp.247-50, 2002.
DOI : 10.1016/S0010-7824(02)00366-9

S. Raghavan, R. Comendant, and I. Digol, Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: a randomized controlled trial of sublingual and oral misoprostol, Contraception, vol.79, issue.2, pp.84-90, 2009.
DOI : 10.1016/j.contraception.2008.09.001

B. Winikoff, I. Dzuba, and M. Creinin, Two Distinct Oral Routes of Misoprostol in Mifepristone Medical Abortion, Obstetrics & Gynecology, vol.112, issue.6, pp.1303-1313, 2008.
DOI : 10.1097/AOG.0b013e31818d8eb4

M. Fjerstad, I. Sivin, E. Lichtenberg, J. Trussell, C. K. Cullins et al., Effectiveness of medical abortion with mifepristone and buccal misoprostol through 59 gestational days, Contraception, vol.80, issue.3, pp.282-288, 2009.
DOI : 10.1016/j.contraception.2009.03.010

H. Hamoda, P. Ashok, J. Dow, G. Flett, and A. Templeton, A pilot study of mifepristone in combinationwith sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation, Contraception, 2003.

T. Middleton, E. Schaff, and S. Fielding, Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period, Contraception, vol.72, issue.5, pp.328-360, 2005.
DOI : 10.1016/j.contraception.2005.05.017

K. Kallner, C. Fiala, O. Stephansson, and K. Gemzell-danielsson, Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days, Human Reproduction, vol.25, issue.5, pp.1153-1157, 2010.
DOI : 10.1093/humrep/deq037

E. Chong, T. Tsereteli, N. Nguyen, and B. Winikoff, A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. Contraception, pp.251-257, 2012.

P. Goldstone, J. Michelson, and E. Williamson, Early medical abortion using low-dose mifepristone followed by buccal misoprostol: a large Australian observational study, The Medical Journal of Australia, vol.197, issue.5
DOI : 10.5694/mja12.10297

K. Coyaji, U. Krishna, and S. Ambardekar, Are two doses of misoprostol after mifepristone for early abortion better than one?, BJOG: An International Journal of Obstetrics & Gynaecology, vol.284, issue.3, pp.271-279, 2007.
DOI : 10.1111/j.1471-0528.2006.01208.x

M. Reeves, A. Kudva, and M. Creinin, Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac, Contraception, vol.78, issue.4, pp.332-335, 2008.
DOI : 10.1016/j.contraception.2008.06.002

O. Tang, H. Schweer, S. Lee, and P. Ho, Pharmacokinetics of repeated doses of misoprostol, Human Reproduction, vol.24, issue.8, pp.1862-1869, 2009.
DOI : 10.1093/humrep/dep108

E. Schaff, Evidence for shortening the time interval of prostaglandin after mifepristone for medical abortion, Contraception, vol.74, issue.1, pp.42-46, 2006.
DOI : 10.1016/j.contraception.2006.03.014

L. Wedisinghe and D. Elsandabesee, Flexible mifepristone and misoprostol administration interval for first-trimester medical termination. Contraception, 2010.

M. Løkeland, O. Iversen, A. Engeland, I. Økland, and L. Bjørge, Medical abortion with mifepristone and home administration of misoprostol up to 63??days' gestation, Acta Obstetricia et Gynecologica Scandinavica, vol.119, issue.2 Pt 1, pp.647-53
DOI : 10.1111/aogs.12398

D. Thoai, . Ngo, M. Park, H. Shakur, and C. Free, Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review. Bull World Health Organ, pp.360-370, 2011.

E. Jackson and N. Kapp, Pain control in first-trimester and second-trimester medical termination of pregnancy: a systematic review, Contraception, vol.83, issue.2, pp.116-142, 2011.
DOI : 10.1016/j.contraception.2010.07.014

A. Livshits, R. Machtinger, L. David, M. Spira, A. Moshe-zahav et al., Ibuprofen and paracetamol for pain relief during medical abortion: a double-blind randomized controlled study, Fertility and Sterility, vol.91, issue.5, pp.1877-80, 2009.
DOI : 10.1016/j.fertnstert.2008.01.084

S. Suhonen, . Marjatikka, T. Seppokivinen, and . Kauppila, Pain during medical abortion: predicting factors from gynecologic history and medical staff evaluation of severity, Contraception, vol.83, issue.4, pp.357-361, 2011.
DOI : 10.1016/j.contraception.2010.08.006

M. Fischer, . Bhatnagarj, and J. Guarner, after Medical Abortion, New England Journal of Medicine, vol.353, issue.22, pp.2352-60, 2005.
DOI : 10.1056/NEJMoa051620

H. Liang, E. Gao, A. Chen, L. Luo, Y. Cheng et al., Mifepristone-induced abortion and vaginal bleeding in subsequentpregnancy, Contraception, 2011.

N. Winer, M. Resche-rigon, C. Morin, Y. Ville, and P. Rozenberg, Is induced abortion with misoprostol a risk factor for late abortion or preterm delivery in subsequent pregnancies?, European Journal of Obstetrics & Gynecology and Reproductive Biology, vol.145, issue.1, pp.53-59, 2009.
DOI : 10.1016/j.ejogrb.2009.04.028

T. Munk-olsen, T. Laursen, C. Pedersen, O. Lidegaard, and P. Mortensen, Induced First-Trimester Abortion and Risk of Mental Disorder, New England Journal of Medicine, vol.364, issue.4, 2011.
DOI : 10.1056/NEJMoa0905882

B. Major, M. Appelbaum, L. Beckman, M. Dutton, N. Russo et al., Abortion and mental health: Evaluating the evidence., American Psychologist, vol.64, issue.9, 2009.
DOI : 10.1037/a0017497

B. Winikoff, C. Ellertson, and S. Clark, Analysis of failure in medical abortion, Contraception, vol.54, issue.6, pp.323-330, 1996.
DOI : 10.1016/S0010-7824(96)00206-5

E. Horning, B. Chen, L. Meyn, and M. Creinin, Comparison of medical abortion follow-up with serum human chorionic gonadotropin testing and in-office assessment, Contraception, pp.402-409, 2012.

C. Auvara, Observance de la consultation post-IVG médicamenteuse dans la métropole Nice Côte d'Azur : enquête de 3 mois auprès de 160 patientes [Thèse d'exercice, 2013.

B. Chen, L. Meyn, and M. Creinin, Outcome of medical abortion through 63 days in women with prior cesarean section, Contraception, vol.76, issue.2, p.163, 2007.
DOI : 10.1016/j.contraception.2007.05.023

N. Menage, D. Loundou, C. Chau, L. Cravallo, M. Gamerre et al., Facteurs cliniques et échographiques influençant le succès du misoprostol pour grossesse arrêtée au premier trimestre. Gynécologie Obstétrique & Fertilité, Feb, vol.40, issue.2, pp.84-87, 2012.

L. Chien, W. Liu, C. Tzeng, and H. Au, Effect of Previous Live Birth and Prior Route of Delivery on the Outcome of Early Medical Abortion, Obstetrics & Gynecology, vol.113, issue.3, 2009.
DOI : 10.1097/AOG.0b013e31819638e6

R. Haimov-kochman, R. Arbel, Y. Sciaky-tamir, A. Brzezinski, N. Laufer et al., Risk factors for unsuccessful medical abortion with mifepristone and misoprostol, Acta Obstetricia et Gynecologica Scandinavica, vol.86, issue.4, pp.462-466, 2007.
DOI : 10.1080/00016340701203632

S. Alice, Évaluation de l'efficacité de l'IVG médicamenteuse en Ariège et recherche des principaux facteurs d'échecs

S. Charlotte, Facteurs d'échec de l'interruption volontaire de grossesse réalisée par méthode médicamenteuse jusqu'à 9 semaines d'aménorrhée dans un centre d'orthogénie de l

P. Delphine and B. Christine, Facteurs de risque d'échec de la méthode médicamenteuse d'interruption volontaire de grossesse jusqu'à 49 jours d'aménorrhée [Thèse d'exercice : Médecine Générale], 2008.

P. Ashok, A. Templeton, P. Wagaarachchi, and G. Flett, Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases, BJOG: An International Journal of Obstetrics and Gynaecology, vol.99, issue.2, 2002.
DOI : 10.1016/S0010-7824(00)00090-1

B. Kruse, S. Poppema, M. Creinin, and M. Paul, Management of side effects and complications in medical abortion American Journal of Obstetric and gynecology, pp.65-75, 2000.

P. Faucher and D. Hassoun, Interruption Volontaire de Grossesse médicamenteuse, 2011.

M. Fjerstad, J. Trussell, I. Sivin, E. Lichtenberg, and V. Cullins, Rates of Serious Infection after Changes in Regimens for Medical Abortion, New England Journal of Medicine, vol.361, issue.2, pp.145-151, 2009.
DOI : 10.1056/NEJMoa0809146

P. Faucher, N. Baunot, and P. Madelenat, Efficacit?? et acceptabilit?? de l'interruption volontaire de grossesse par m??thode m??dicamenteuse pratiqu??e sans hospitalisation dans le cadre d'un r??seau ville???h??pital??: ??tude prospective sur 433 patientes, Gyn??cologie Obst??trique & Fertilit??, vol.33, issue.4
DOI : 10.1016/j.gyobfe.2005.02.021

T. Shochet, A. Diop, and A. Gaye, Sublingual misoprostol versus standard surgical care for treatment of incomplete abortion in five sub-Saharan African countries, BMC Pregnancy and Childbirth, vol.113, issue.4, p.127, 2012.
DOI : 10.1097/AOG.0b013e31819930f9

F. Cayre, Evaluation de l'efficacité et des facteurs de risque d'échecs des IVG médicamenteuses à partir d'une description de 4153 cas [Thèse d'exercice : Médecine Générale], 2010.